Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
细胞生物学 囊泡 肿瘤 内分泌与代谢疾病
/
细胞培养
细胞周期 帕金森与阿尔茨海默症 Wnt Signaling Pathway Hedgehog (Hh) 乳腺癌 前列腺癌 衰老
/
类器官培养添加剂
CDK
/ Palbociclib/帕博西尼

Palbociclib/帕博西尼 {[allProObj[0].p_purity_real_show]}

货号：A295334 同义名： 帕布昔利布 / PD 0332991

Palbociclib是一种高度特异性的Cdk4和Cdk6抑制剂，IC50分别为11 nM和16 nM。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Palbociclib/帕博西尼 化学结构 CAS号：571190-30-2
Palbociclib/帕博西尼 化学结构
CAS号：571190-30-2
Palbociclib/帕博西尼 3D分子结构
CAS号：571190-30-2
Palbociclib/帕博西尼 化学结构 CAS号：571190-30-2
Palbociclib/帕博西尼 3D分子结构 CAS号：571190-30-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Palbociclib/帕博西尼 纯度/质量文件 产品仅供科研

货号：A295334 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 Cdc ↓ CDK1 ↓ CDK19 ↓ CDK2 ↓ CDK3 ↓ CDK4 ↓ CDK5 ↓ CDK6 ↓ CDK7 ↓ CDK8 ↓ CDK9 ↓ CLK ↓ 其他靶点 纯度
XL413 HCl ++++

Cdc7, IC50: 3.4 nM

 		99%+
SU9516 +++

CDK1, IC50: 40 nM

 		+++

CDK2, IC50: 22 nM

 		++

CDK4, IC50: 200 nM

 		99%+
RO-3306 +++

CDK1, Ki: 20 nM

 		SGK,ERK 98%
R547 ++++

CDK1/CyclinB, Ki: 2 nM

 		++++

CDK2/CyclinE, Ki: 3 nM

 		++++

CDK4/CyclinD1, Ki: 1 nM

 		99%+
BMS-265246 ++++

CDK1/CyclinB, IC50: 6 nM

 		++++

CDK2/CyclinE, IC50: 9 nM

 		+

CDK4/CyclinD, IC50: 230 nM

 		99%+
NU6027 +

CDK1, Ki: 2.5 μM

 		+

CDK2, Ki: 1.3 μM

 		DNA-PK 98%
Purvalanol A ++++

Cdc2/CyclinB, IC50: 4 nM

 		+++

CDK2/CyclinE, IC50: 35 nM

CDK2/CyclinA, IC50: 70 nM

 		+

CDK4/CyclinD1, IC50: 850 nM

 		99%+
SCH900776 ++

CDK2, IC50: 0.16 μM

 		99%+
AUZ 454 ++++

CDK2(C118L), Kd: 18.6 nM

CDK2(A144C), Kd: 9.7 nM

 		99%+
A-674563 HCl ++

CDK2, Ki: 46 nM

 		PKA 99%
JNJ-7706621 ++++

CDK1/CyclinB, IC50: 9 nM

 		++++

CDK2/CyclinE, IC50: 3 nM

CDK2/CyclinA, IC50: 4 nM

 		++

CDK3/CyclinE, IC50: 58 nM

 		+

CDK4/CyclinD1, IC50: 253 nM

 		++

CDK6/CyclinD1, IC50: 175 nM

 		99%+
AT7519 ++

CDK1/CyclinB, IC50: 210 nM

 		++

CDK2/CyclinA, IC50: 47 nM

 		+

CDK3/CyclinE, IC50: 360 nM

 		++

CDK4/CyclinD1, IC50: 100 nM

 		+++

CDK5/p35, IC50: 13 nM

 		++

CDK6/CyclinD3, IC50: 170 nM

 		++++

CDK9/CyclinT, IC50: <10 nM

 		98+%
PHA-793887 ++

CDK1/CyclinB, IC50: 60 nM

 		++++

CDK2/CyclinE, IC50: 8 nM

CDK2/CyclinA, IC50: 8 nM

 		++

CDK4/CyclinD1, IC50: 62 nM

 		++++

CDK5/p25, IC50: 5 nM

 		++++

CDK7/CyclinH, IC50: 10 nM

 		++

CDK9/CyclinT1, IC50: 138 nM

 		99%+
Milciclib +

CDK1/CyclinB, IC50: 398 nM

 		++

CDK2/CyclinE, IC50: 363 nM

CDK2/CyclinA, IC50: 45 nM

 		++

CDK4/CyclinD1, IC50: 160 nM

 		+

CDK5/p35, IC50: 265 nM

 		++

CDK7/CyclinH, IC50: 150 nM

 		99%+
Kenpaullone +

CDK1/CyclinB, IC50: 0.4μM

 		+

CDK2/CyclinE, IC50: 7.5μM

CDK2/CyclinA, IC50: 0.68μM

 		+

CDK5/p35, IC50: 0.85μM

 		98%
SNS-032 +++

CDK2/CyclinE, IC50: 48 nM

CDK2/CyclinA, IC50: 38 nM

 		+

CDK5/p35, IC50: 340 nM

 		++

CDK7/CyclinH, IC50: 62 nM

 		++++

CDK9/CyclinT, IC50: 4 nM

 		99%+
Dinaciclib ++++

CDK1, IC50: 3 nM

 		++++

CDK2, IC50: 1 nM

 		++++

CDK5, IC50: 1 nM

 		++++

CDK9, IC50: 4 nM

 		99%+
PHA-767491 HCl ++++

Cdc7, IC50: 10 nM

 		+

CDK1, IC50: 250 nM

 		+

CDK2, IC50: 240 nM

 		+

CDK5, IC50: 460 nM

 		+++

CDK9, IC50: 34 nM

 		MK2 99%
(R)-Roscovitine +

Cdc2/CyclinB, IC50: 0.65 μM

 		+

CDK2/CyclinE, IC50: 0.7 μM

CDK2/CyclinA, IC50: 0.7 μM

 		++

CDK5/p35, IC50: 0.16 μM

 		99%+
Narazaciclib ++++

CDK4/CyclinD1, IC50: 3.87 nM

 		++++

CDK6/CyclinD1, IC50: 9.82 nM

 		RET 99%+
Palbociclib ++++

CDK4/CyclinD3, IC50: 9 nM

CDK4/CyclinD1, IC50: 11 nM

 		+++

CDK6/CyclinD2, IC50: 15 nM

 		99%
Abemaciclib ++++

CDK4, IC50: 2 nM

 		++++

CDK6, IC50: 10 nM

 		99%
Ribociclib ++++

CDK4, IC50: 10 nM

 		+++

CDK6, IC50: 39 nM

 		98%
Palbociclib isethionate ++++

CDK4/CyclinD3, IC50: 9 nM

CDK4/CyclinD1, IC50: 11 nM

 		+++

CDK6/CyclinD2, IC50: 15 nM

 		99%+
BS-181 HCl +++

CDK7, IC50: 21 nM

 		99%+
(E/Z)-THZ1 2HCl ++++

CDK7, IC50: 3.2 nM

 		99%+
LDC4297 ++++

CDK7, IC50: 0.13 nM

 		99%+
Senexin A +

CDK19, Kd: 0.31 μM

 		+

CDK8, Kd: 0.83 μM

 		99%
MSC2530818 ++++

CDK8, IC50: 2.6 nM

 		99%+
Wogonin ✔ 99%+
Riviciclib HCl ++

CDK1/CyclinB, IC50: 79 nM

 		+

CDK2/CyclinE, IC50: 2.54 μM

CDK2/CyclinA, IC50: 224 nM

 		++

CDK4/CyclinD1, IC50: 63 nM

 		+

CDK6/CyclinD3, IC50: 396 nM

 		+

CDK7/CyclinH, IC50: 2.87 μM

 		+++

CDK9/CyclinT1, IC50: 20 nM

 		98%
LDC000067 +

CDK2, IC50: 2.441 μM

 		++

CDK9, IC50: 44 nM

 		98%
Flavopiridol +++

CDK1, IC50: 40 nM

 		+++

CDK2, IC50: 40 nM

 		+++

CDK4, IC50: 40 nM

 		+++

CDK6, IC50: 40 nM

 		+

CDK7, IC50: 300 nM

 		+++

CDK9, IC50: 20 nM

 		99%+
LY2857785 +

CDK7, IC50: 0.246 μM

 		+++

CDK8, IC50: 0.016 μM

 		+++

CDK9, IC50: 0.011 μM

 		99%+
AZD-5438 +++

CDK1, IC50: 16 nM

 		++++

CDK2, IC50: 6 nM

 		+++

CDK9, IC50: 20 nM

 		99%+
ML167 ++

Dyrk1B , IC50: 1648 nM

CLK4, IC50: 136 nM

 		99%+
(E/Z)-TG003 +++

mCLK1, IC50: 200 nM

mCLK4, IC50: 15 nM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Palbociclib/帕博西尼 生物活性

靶点

  • CDK4

    CDK4/CyclinD3, IC50:9 nM

    CDK4/CyclinD1, IC50:11 nM

  • CDK6

    CDK6/CyclinD2, IC50:15 nM
描述 Palbociclib (PD 0332991) is an orally active, selective inhibitor of CDK4 and CDK6, showing IC50 values of 11 nM and 16 nM respectively. It exhibits strong anti-proliferative properties and is capable of inducing cell cycle arrest in cancer cells. This makes it a valuable agent in the study of HR-positive and HER2-negative breast cancer as well as hepatocellular carcinoma[1].[3].[4].
体内研究

When administered orally at doses of 75 or 150 mg/kg daily for 14 days, Palbociclib leads to rapid tumor regressions and delays in tumor growth[1].

An oral dose of 90 mg/kg daily for 12 days decreases Treg numbers and the Treg:CD8 ratio in the spleen and lymph nodes of tumor-free mice, indicating its effects independent of tumors[2].

At a dose of 100 mg/kg administered daily for one week, Palbociclib demonstrates significant anti-tumor activity in a genetically engineered mosaic mouse model of liver cancer[4].
体外研究

In laboratory tests, Palbociclib (0-1 μM, over 24 hours) inhibits Rb phosphorylation at Ser795 in MDA-MB-435 cells with an IC50 of 0.063 μM. It shows comparable effects on phosphorylation at both Ser780 and Ser795 in Colo-205 colon carcinoma cells[1].

Additionally, Palbociclib (0-10 μM, over 24 hours) specifically arrests MDA-MB-453 breast cancer cells in the G1 phase[1].

Over a period of 7 days, a 500 nM concentration of Palbociclib boosts the expression of homologous genes (H2d1, H2k1, and B2m) in MDA-MB-453 and MDA-MB-361 cells[2].

Palbociclib inhibits growth in various luminal ER-positive and HER2-amplified breast cancer cell lines when applied at concentrations from 0-1 μM for 6 days, with IC50 values ranging between 4 nM and 1 μM[3].

In human liver cancer cell lines, Palbociclib (0-1 μM, over 3 days) restricts proliferation with IC50 values from 0.01 μM to 3.49 μM and induces reversible cell cycle arrest[4].
作用机制 Palbociclib can inhibit CDK4/6 in an ATP-competitive manner through its pyridopyrimidine structure[1][3][4].

Palbociclib/帕博西尼 细胞实验

Cell Line
Concentration Treated Time Description References
NCI-H1944 cells 100 nM 4 days Evaluate the growth inhibitory effect of alectinib and palbociclib combination on NCI-H1944 cells, showing no enhanced growth inhibition. Cancer Biol Ther. 2020 Sep 1;21(9):863-870
Ba/F3-KIF5B-RET cells 100 nM 4 days Evaluate the growth inhibitory effect of alectinib and palbociclib combination on Ba/F3-KIF5B-RET cells, showing significantly enhanced growth inhibition. Cancer Biol Ther. 2020 Sep 1;21(9):863-870
LC-2/ad cells 100 nM 4 days Evaluate the growth inhibitory effect of alectinib and palbociclib combination on LC-2/ad cells, showing significantly enhanced growth inhibition. Cancer Biol Ther. 2020 Sep 1;21(9):863-870
CHL-1 0.5 μM 24 h Palbociclib induced G0/G1 cell cycle arrest but did not lead to cell death. Cancer Res. 2016 Sep 15;76(18):5455-66.
A375 0.5 μM 24 h Palbociclib induced G0/G1 cell cycle arrest but did not lead to cell death. Cancer Res. 2016 Sep 15;76(18):5455-66.
KPC1 PDAC cells 500 nM 8 days Induced cellular senescence and evaluated SASP-related gene expression Nat Cancer. 2023 Jun;4(6):872-892.
KPC2 PDAC cells 500 nM 8 days Induced cellular senescence and evaluated SASP-related gene expression Nat Cancer. 2023 Jun;4(6):872-892.
C4–2b cells 100 nM and 1 μM 48 h To evaluate the effects of Palbociclib on prostate cancer cell growth, the results showed that Palbociclib combined with Olaparib significantly inhibited cell growth and induced apoptosis. Mol Cancer Ther. 2021 Sep;20(9):1680-1691.
C4–2b-ENZR cells 100 nM and 1 μM 48 h To evaluate the effects of Palbociclib on enzalutamide-resistant prostate cancer cells, the results showed that Palbociclib combined with Olaparib significantly inhibited cell growth and induced apoptosis. Mol Cancer Ther. 2021 Sep;20(9):1680-1691.
NCI-H660 cells 100 nM and 1 μM 48 h To evaluate the effects of Palbociclib on neuroendocrine prostate cancer cells, the results showed that Palbociclib combined with Olaparib significantly inhibited cell growth and induced apoptosis. Mol Cancer Ther. 2021 Sep;20(9):1680-1691.
MCF-7 1–100nM 1 h Palbociclib significantly increased radiosensitivity in MCF-7 cells, with a radiation enhancement ratio (rER) of 1.15–1.67. Clin Cancer Res. 2020 Dec 15;26(24):6568-6580.
T47D 1–100nM 1 h Palbociclib significantly increased radiosensitivity in T47D cells, with a radiation enhancement ratio (rER) of 1.12–1.65. Clin Cancer Res. 2020 Dec 15;26(24):6568-6580.
MCF-7 500 nM 48 h To study the effect of Palbociclib on MCF-7 cells, results showed that Palbociclib could inhibit cell proliferation. Breast Cancer Res. 2020 Aug 12;22(1):87.
MCF-7 PalbR 500 nM 48 h To study the effect of Palbociclib on MCF-7 PalbR cells, results showed that Palbociclib could inhibit cell proliferation and induce cellular senescence. Breast Cancer Res. 2020 Aug 12;22(1):87.
SK-MEL-103 cells 2 μM 1 week Induced cellular senescence and increased expression of lysosomal membrane proteins LAMP1 and LAMP2 Aging Cell. 2022 Oct;21(10):e13707.
Huh7 cells 2 μM 1 week Induced cellular senescence and increased expression of lysosomal membrane proteins LAMP2A, GBA, and CTSD Aging Cell. 2022 Oct;21(10):e13707.
U2OS cells 2 μM 1 week Induced cellular senescence and increased expression of lysosomal membrane proteins LAMP2A, GBA, and CTSD Aging Cell. 2022 Oct;21(10):e13707.
human fibroblasts 1 μM 10 days Induced cellular senescence, observed changes in cell size Cell. 2019 Feb 21;176(5):1083-1097.e18.
RPE-1 cells 1 μM 16 h To synchronize cells at the G1/S transition and study DNA damage levels post-tetraploidization. Nature. 2022 Apr;604(7904):146-151.

Palbociclib/帕博西尼 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c-nu/nu mice Ba/F3-KIF5B-RET xenograft model Orally 75 mg/kg Daily from Day 1 for 11 days Evaluate the antitumor effect of alectinib and palbociclib combination on Ba/F3-KIF5B-RET xenograft model, showing significantly enhanced antitumor effect. Cancer Biol Ther. 2020 Sep 1;21(9):863-870
Nude mice MDA-MB-231 xenograft model Oral 100 mg/kg Twice a week for 21 days Study the effect of Mycro 3 on palbociclib sensitivity in vivo, found that Mycro 3 combined with palbociclib significantly inhibited tumor growth Cell Death Dis. 2020 Sep 15;11(9):760
Mice Pancreatic cancer transplant model Oral 100 mg/kg 4 consecutive days followed by 3 days off treatment for 2 weeks Evaluated the effect of Palbociclib combined with Trametinib on tumor growth and immune response in pancreatic cancer Nat Cancer. 2023 Jun;4(6):872-892.
Mice 1205Lu xenograft model Oral 429 mg/kg Once daily for 51 days Palbociclib monotherapy initially suppressed 1205Lu tumor growth in vivo but progressive growth ensued. Cancer Res. 2016 Sep 15;76(18):5455-66.
Male nude mice C4–2b-ENZR and NCI-H660 xenograft models Oral gavage 100 mg/kg 5 days each week, for 15 days (C4–2b-ENZR model) or 21 days (NCI-H660 model) To evaluate the effects of Palbociclib combined with Olaparib on tumor growth in prostate cancer xenograft models, the results showed that the combination treatment significantly inhibited tumor growth and induced tumor cell apoptosis. Mol Cancer Ther. 2021 Sep;20(9):1680-1691.
CB17-SCID mice MCF-7 xenograft model Oral 25mg/kg Once daily for 6 days Palbociclib combined with radiation significantly suppressed tumor growth and prolonged time to tumor doubling. Clin Cancer Res. 2020 Dec 15;26(24):6568-6580.
Mice Patient-derived xenograft (PDX) model Oral 100 mg/kg 5 days a week for 60 days To study the effect of Palbociclib on ER-positive breast cancer in vivo, results showed that Palbociclib could significantly inhibit tumor growth. Breast Cancer Res. 2020 Aug 12;22(1):87.

Palbociclib/帕博西尼 动物研究

Dose Rat: 25 mg/kg[6] (i.p.); 1 mg/kg - 5 mg/kg[5] (i.v.) Mice: 100 mg/kg[7] (i.g., b.w.), 25 mg/kg - 125 mg/kg[8] (p.o.), 5 mg/kg - 200 mg/kg[5] (p.o.)
Administration i.p., i.g., p.o.
Pharmacokinetics
Animal Rats[5]
Dose 5 mg/kg
Administration i.v. or p.o.
Vd 7070 ml/kg (i.v.)
T1/2 2.60 h (i.v.)
2.3 h (p.o.)
Tmax 0.08 h (i.v.)
3.5 h (p.o.)
CL 37 ml/min/kg (i.v.)
Cmax 2507 ng/ml (i.v.)
178 ng/ml (p.o.)
AUC0→t 2160 ng·h/ml (i.v.)
1140 ng·h/ml (p.o.)

Palbociclib/帕博西尼 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03007979 Breast Cancer ... 展开 >> Breast Carcinoma Cancer of Breast Malignant Tumor of Breast 收起 << Phase 2 Recruiting June 30, 2021 United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Cynthia X Ma, M.D., Ph.D.    314-362-9383    cynthiaxma@wustl.edu    Principal Investigator: Cynthia X Ma, M.D., Ph.D.          Sub-Investigator: Foluso O Ademuyiwa, M.D.          Sub-Investigator: Ron Bose, M.D., Ph.D.          Sub-Investigator: Mathew Cherian, M.D.          Sub-Investigator: Ashley Frith, M.D.          Sub-Investigator: Leonel Hernandez Aya, M.D.          Sub-Investigator: Peter Oppelt, M.D.          Sub-Investigator: Haeseong Park, M.D.          Sub-Investigator: Caron Rigden, M.D.          Sub-Investigator: Rama Suresh, M.D.          Sub-Investigator: Katherine Weilbaecher, M.D.          Sub-Investigator: Rebecca Aft, M.D., Ph.D.          Sub-Investigator: Lindsay Peterson, M.D.          United States, Nebraska University of Nebraska Recruiting Lincoln, Nebraska, United States, 68588 Contact: Jairam Krishnamurthy, M.D.    402-559-1800    jairam.krishnamurthy@unmc.edu    Principal Investigator: Jairam Krishnamurthy, M.D.          Sub-Investigator: Kenneth Cowan, M.D.          Sub-Investigator: Elizabeth Reed, M.D.          Sub-Investigator: Pavankumar Tandra, M.D. 收起 <<
NCT01907607 Advanced Gastrointestinal Stro... 展开 >>mal Tumors 收起 << Phase 2 Active, not recruiting April 2019 France ... 展开 >> Institut Bergonié Bordeaux, Gironde, France, 33076 Centre Georges-Francois Leclerc Dijon, France, 21079 Centre Oscar Lambret Lille, France, 59020 Centre Léon Bérard Lyon, France, 69373 Hôpital de la Timone - AP-HM Marseille, France, 13385 Centre René Gauducheau Nantes, France, 44805 Hôpital Saint-Antoine (AP-HP) Paris, France, 75571 CHU de REIMS - Hôpital Robert Debré Reims, France, 51092 Institut Gustave Roussy Villejuif, France, 94800 收起 <<
NCT03304080 Breast Neoplasms ... 展开 >> Breast Diseases 收起 << Phase 1 Phase 2 Recruiting November 1, 2019 United States, New York ... 展开 >> Mount Sinai Beth Israel Comprehensive Cancer Center West Recruiting New York, New York, United States, 10011 Contact: Paula Klein, MD    212-604-6021    paula.klein@mountsinai.org    Perlmutter Cancer Center NYU Langone Not yet recruiting New York, New York, United States, 10016 Contact: Sylvia Adams, MD    212-731-5795    sylvia.adams@nyumc.org    Sub-Investigator: Sylvia Adams, MD          Mount Sinai West Recruiting New York, New York, United States, 10019 Contact: Krystal Cascetta, MD    212-523-8692    krystal.cascetta@mountsinai.org    New York Presbyterian Herbert Irving Comprehensive Cancer Center at Columbia University Not yet recruiting New York, New York, United States, 10032 Contact: Kevin Kalinsky, MD    212-305-1945    Kk2693@columbia.edu    New York Presbyterian Meyer Cancer Center at Weill Cornell Not yet recruiting New York, New York, United States, 10065 Contact: Eleni Andreopoulou, MD    646-962-9888    ela9082@med.cornell.edu 收起 <<

Palbociclib/帕博西尼 参考文献

[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.

[2]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475.

[3]Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.

[4]Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296.

Palbociclib/帕博西尼 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.17mL

2.23mL

1.12mL

22.34mL

4.47mL

2.23mL

Palbociclib/帕博西尼 技术信息

CAS号571190-30-2
分子式C24H29N7O2
分子量 447.53
SMILES Code O=C1C(C(C)=O)=C(C)C2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C5CCCC5
MDL No. MFCD11840850
别名 帕布昔利布 ;PD 0332991
运输蓝冰
InChI Key AHJRHEGDXFFMBM-UHFFFAOYSA-N
Pubchem ID 5330286
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, room temperature
溶解方案

DMSO: 10 mg/mL(22.34 mM)，配合低频超声，水浴加热至45℃，并调节pH至4，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

0.1 M HCL: 25 mg/mL(55.86 mM)，配合低频超声，并调节pH至4

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案 一
方案 二

Tags: Palbociclib | PD 0332991 | 帕布昔利布 | CDK | AmBeed-信号通路专用抑制剂 | Palbociclib/帕博西尼 纯度/质量文件 | Palbociclib/帕博西尼 亚型比较 | Palbociclib/帕博西尼 生物活性 | Palbociclib/帕博西尼 动物研究 | Palbociclib/帕博西尼 临床数据 | Palbociclib/帕博西尼 参考文献 | Palbociclib/帕博西尼 实验方案 | Palbociclib/帕博西尼 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z